Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/08—Peptides having 5 to 11 amino acids
  • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/08—Peptides having 5 to 11 amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/08—Drugs for disorders of the urinary system of the prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
  • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T428/00—Stock material or miscellaneous articles
  • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Definitions

• Composition for the treatment of benign prostate hyperplasia is provided.
• the present invention relates to compositions for the treatment of benign prostatic hyperplasia (BPH), and methods of treatment of BPH using these compositions.
• BPH benign prostatic hyperplasia
• BPH benign prostatic hyperplasia
• benign prostatic hypertrophy is a condition where an abnormal proliferation of prostate cells causes a benign enlargement of the organ which may eventually lead to urinary obstruction and lower urinary tract symptoms.
• BPH affects more than 50% of men over age 60 and as many as 90% of men over the age of 70.
• BPH may be treated by surgery to remove prostatic tissue. This reduces the physical bulk of the prostate, thereby reducing obstruction and urinary symptoms.
• Transurethral resection of the prostate (TURP) is the gold standard surgical treatment for urinary symptoms due to BPH. The procedure is effective and tolerated reasonably well, although associated with postoperative morbidity like urinary incontinence and retrograde ejaculation. As a consequence, although TURP is effective, it is considered as a last resort, and medicinal therapy has become the first line treatment of symptomatic BPH.
• the primary treatment goals for men with BPH are to alleviate lower urinary tract symptoms and prevent the progression of the disease, in particular the risk of acute urinary retention and need for surgery.
• the risk of progression is directly related to the prostate volume. Therefore, drugs that reduce prostate volume have been shown to exhibit the greatest effect in preventing the disease progression.
• Two classes of drugs, ⁇ -blockers and 5- ⁇ -reductase inhibitors, are presently approved by authorities for treatment of BPH. Only the 5- ⁇ -reductase inhibitors, either alone or in combination with ⁇ -blockers, have been shown to reduce prostate volume and prevent the risks of acute urinary retention and need for BPH surgery.
• a pharmaceutical composition for (use in) the treatment of benign prostate hyperplasia comprising 4 mg to 79 mg (for example 9 to 33 mg) degarelix or pharmaceutically acceptable salt thereof (e.g. acetate); and a solvent; wherein the concentration of the degarelix or salt thereof in the solvent is from 5 to 80 mg/mL, for example 10 to 75 mg/mL, for example 20 to 60 mg/mL, for example 25 to 50 mL, for example 35 to 45mg/mL (for example, 40mg/mL).
• the composition may be for administration by injection (e.g. by syringe, e.g. by double chamber syringe, or double chamber cartridge e.g. for an injector "pen", as are well known in the art).
• the composition is for administration as a single dose.
• the composition may be administered in one or more doses, for example two doses, separated, for example, by an interval of 1 to 21 days, for example 14 days.
• the composition may further comprise an excipient (e.g. a sugar, e.g. a sugar alcohol, e.g. mannitol).
• the degarelix or salt thereof may be a colyophilisate with the excipient.
• the solvent may be, for example, water, or a mixture of water and mannitol.
• the composition may comprise, for example, 4 mg, 8 mg, 10 mg, 15 mg, 16 mg, 20 mg, 24 mg, 25 mg, 30 mg, 32 mg, 36 mg, 40 mg, 45 mg, 50 mg or 64 mg of degarelix or salt thereof.
• the composition may comprise, for example, from 9 to 33 mg degarelix or salt thereof, for example 10 to 30 mg degarelix or salt thereof, for example 12 to 28 mg degarelix or salt thereof, for example 15 to 25 mg degarelix or salt thereof, for example 17 to 23 mg degarelix or salt thereof.
• the composition may comprise, for example, from 10 to 40 mg degarelix or salt thereof.
• the composition may be at a concentration of degarelix (or salt thereof) in the solvent of 5, 10, 15, 20, 25, 30, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 50, 55, 60, 65, 70, 75 or 80 mg/mL, preferably 40 mg/mL.
• compositions according to the invention include 10 mg, 16 mg, 20 mg, 30 mg or 32 mg degarelix (e.g. as degarelix acetate); and solvent (e.g. water), wherein concentration of the degarelix (e.g. acetate) in the solvent is 40mg/mL.
• degarelix e.g. as degarelix acetate
• solvent e.g. water
• degarelix a synthetic decapeptide antagonist of GnRH which has been approved for use in treatment of prostate cancer.
• An application for marketing authorisation/new drug application for a formulation for monthly administration was submitted to the FDA and EMEA in February 2008.
• an effective dose is one which reduces the level of testosterone in the serum to below castration levels, that is to below a serum concentration of 50 ng/dL (0.5 ng/L), and maintains plasma testosterone at this level.
• Such doses are generally in the region of 240 mg or even higher.
• compositions according to the invention may be effective in the treatment of BPH when administered periodically, for example once every 3 to 18 months, for example once every 6 or 12 months.
• a composition comprising 30 or 32 mg degarelix and water, at a concentration of degarelix in water of 40 mg/mL, is administered once every 6 or 12 months.
• the composition may be administered as, for example, two compositions/doses of 15 mg (or 16 mg) degarelix separated by an interval of, for example, 14 days (with a further administration of composition in either one or two doses after e.g. 12 months).
• treatment of benign prostate hyperplasia includes treatment to alleviate one or more lower urinary tract symptoms associated with BPH (e.g. so called “storage symptoms” such as frequency of urination, urgency of urination, dysuria, nocturia, urgency incontinence ; and/or "voiding symptoms” such as poor stream, hesitancy, terminal dribbling, incomplete voiding, overflow incontinence) as indicated by a reduction in the IPSS score as discussed below; treatment to delay or prevent disease progression and/or reduce the risk of acute urinary retention and/or reduce or delay the need for surgery, and/or treatment to reduce volume of the prostate gland, and/or treatment to increase quality of life of the patient (e.g. as indicated by an improvement in the IPSS QOL survey, see below, or an improvement in the BPH Impact Index), and/or treatment to improve (increase) Qmax (see below).
• storage symptoms such as frequency of urination, urgency of urination, dysuria, nocturia, urgency incontine
• a (pharmaceutical) preparation comprising 4 mg to 79 mg, for example 9 to 33 mg, degarelix or pharmaceutically acceptable salt thereof (e.g. acetate); and a solvent, wherein the concentration of the degarelix or salt thereof in the solvent is from 5 to 80 mg/mL, for example 10 to 75 mg/mL, for example 20 to 60 mg/mL, for example 25 to 50 mL, for example 35 to 45mg/mL (for example, 40mg/mL).
• the preparation may further comprise an excipient (e.g. a sugar, e.g. a sugar alcohol, e.g. mannitol).
• the degarelix or salt thereof my be a colyophilisate with the excipient.
• the solvent may be, for example, water, or a mixture of water and mannitol.
• the pharmaceutical preparation may comprise, for example, 4 mg, 8 mg, 10 mg, 15 mg, 16 mg, 20 mg, 24 mg, 25 mg, 30 mg, 32 mg, 36 mg, 40 mg, 45 mg, 50 mg or 64 mg of degarelix or salt thereof.
• the preparation may comprise, for example, from 9 to 33 mg degarelix or salt thereof, for example 10 to 30 mg degarelix or salt thereof, for example 12 to 28 mg degarelix or salt thereof, for example 15 to 25 mg degarelix or salt thereof, for example 17 to 23 mg degarelix or salt thereof.
• the preparation may be at a concentration of degarelix (or salt thereof) in the solvent of 5, 10, 15, 20, 25, 30, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 50, 55, 60, 65, 70, 75 or 80 mg/mL, preferably 40 mg/mL.
• Preferred pharmaceutical preparations according to the invention include 10 mg, 16 mg, 20 mg, 30 mg or 32 mg degarelix (e.g. as degarelix acetate); and solvent (e.g. water), wherein concentration of the degarelix (e.g. acetate) in the solvent is 40mg/mL.
• the pharmaceutical preparation may be administered (for the treatment of BPH) periodically, for example once every 3 to 18 months, for example once every six months or once every year.
• a method of treatment of benign prostate hyperplasia in a subject comprising a step of administering to the subject a pharmaceutical composition comprising 4 mg to 79 mg (for example 9 to 33 mg, 10 to 40 mg) degarelix or pharmaceutically acceptable salt thereof (e.g. acetate); and a solvent (e.g. water); wherein the concentration of the degarelix or salt thereof in the solvent is from 5 to 80 mg/mL, for example 10 to 75 mg/mL, for example 20 to 60 mg/mL, for example 25 to 50 mL, for example 35 to 45mg/mL (for example, 40mg/mL).
• the composition is for administration as a single dose.
• the composition may be administered in one or more doses, for example two doses, separated by an interval of 1 to 21 days, for example 14 days.
• the method may further comprise repeating, at least once, administration of the pharmaceutical compound to the patient from 3 to 18, e.g. 6 to 12, months after the prior administration.
• the pharmaceutical composition may further comprise an excipient (e.g. a sugar, e.g. a sugar alcohol, e.g. mannitol).
• the degarelix or salt thereof may be a colyophilisate with the excipient.
• kits of parts for providing (e.g. reconstituting) a composition (or pharmaceutical preparation) comprising 4 mg to 79 mg (for example 9 to 33 mg, 10 to 40mg) degarelix or pharmaceutically acceptable salt thereof (e.g. acetate); and a solvent; wherein the concentration of the degarelix or salt thereof in the solvent is from 5 to 80 mg/mL, for example 10 to 75 mg/mL, for example 20 to 60 mg/mL, for example 25 to 50 mL, for example 35 to 45mg/mL (for example, 40mg/mL); the kit of parts comprising one or more containers (e.g.
• vials, prefilled syringes etc. of degarelix or pharmaceutically acceptable salt thereof (e.g. as a colyophilisate with an excipient); and one or more containers (e.g. vials, prefilled syringes etc.) of solvent, optionally together with a device for reconstitution.
• the composition may further comprise an excipient (e.g. a sugar, e.g. a sugar alcohol, e.g. mannitol).
• the degarelix or salt thereof may be a colyophilisate with the excipient.
• the solvent may be, for example, water, or a mixture of water and mannitol.
• the composition may comprise, for example, 4 mg, 8 mg, 10 mg, 15 mg, 16 mg, 20 mg, 24 mg, 25 mg, 30 mg, 32 mg, 36 mg, 40 mg, 45 mg, 50 mg or 64 mg of degarelix or salt thereof.
• the composition may comprise, for example, from 9 to 33 mg degarelix or salt thereof, for example 10 to 30 mg degarelix or salt thereof, for example 12 to 28 mg degarelix or salt thereof, for example 15 to 25 mg degarelix or salt thereof, for example 17 to 23 mg degarelix or salt thereof.
• the composition may be at a concentration of degarelix (or salt thereof) in the solvent of 5, 10, 15, 20, 25, 30, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 50, 55, 60, 65, 70, 75 or 80 mg/mL, preferably 40 mg/mL.
• Preferred compositions according to the invention include 16 or 30 or 32 or 64 mg degarelix (e.g. as degarelix acetate); and solvent (e.g. water), wherein concentration of the degarelix (e.g. acetate) in the solvent is 40mg/mL.
• a method of preparing a composition for treating benign prostate hyperplasia comprising: combining at least one first container comprising a composition or pharmaceutical preparation comprising 4 mg to 79 mg (for example 9 to 33 mg, 10 to 40mg) degarelix or pharmaceutically acceptable salt thereof; and at least one second container comprising a solvent (e.g. water); wherein the concentration of the degarelix or salt thereof in the solvent is from 5 to 80 mg/mL, for example 10 to 75 mg/mL, for example 20 to 60 mg/mL, for example 25 to 50 mL, for example 35 to 45mg/ml_ (for example, 40mg/mL).
• the pharmaceutical composition may further comprise an excipient (e.g. a sugar, e.g. a sugar alcohol, e.g. mannitot).
• the degarelix or salt thereof may be a colyophilisate with the excipient.
• Figure 1a is a graphical representation of the IPSS Sum of Scores by visit and dose (initial 42 day study);
• Figure 1 b is a graphical representation of the change from baseline in IPSS, for the initial 42 day study and including follow up at 6, 9 and 12 months;
• Figure 1c states the seven questions (Q1 - Q7) of the IPSS which evaluate symptoms of urinary obstruction (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, nocturia) over the preceding week, together with, for each question, a graphical representation of the IPSS score, by visit and dose (initial 42 day study);
• Figure 2 is a graphical representation of the comparative change in IPSS Score between medicinal and surgical treatments [source: AUA Guideline on the Management of Benign Prostatic Hyperplasia (2006]; and Figure 3 is an overview of the pharmacodynamic endpoints derived from the testosterone concentration/time profile.
• plasma concentration herein is used interchangeably with “plasma trough concentration”.
• administer refers to (i) providing, giving, dosing and/or prescribing degarelix by either a healthcare professional or his or her authorised agent or under his or her direction, and (ii) putting into, taking, or injecting by the patient or person himself or herself, degarelix.
• Degarelix is a potent GnRH antagonist that is an analog of the GnRH decapeptide
• Degarelix is a selective GnRH receptor antagonist (blocker) that competitively and reversibly binds to the pituitary
• GnRH receptors thereby rapidly reducing the release of gonadotrophins and consequently testosterone (T). It is indicated for treatment of patients with prostate cancer in whom androgen deprivation is warranted (including patients with rising PSA levels after having already undergone prostatectomy or radiotherapy). Unlike GnRH agonists, GnRH receptor blockers do not induce a luteinizing hormone (LH) surge with subsequent testosterone surge/tumor stimulation and potential symptomatic flare after the initiation of treatment.
• LH luteinizing hormone
• the active ingredient degarelix is a synthetic linear decapeptide amide containing seven unnatural amino acids, five of which are D-amino acids.
• the drug substance is an acetate salt, but the active moiety of the substance is degarelix as the free base.
• the acetate salt of degarelix is a white to off-white amorphous powder (of low density as obtained after lyophilisation).
• the chemical name is D-Alaninamide, N-acetyl-3-(2- naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[[[(4S)- hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl) amino]-D-phenylalanyl-L leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl.
• Degarelix may be formulated for administration subcutaneously (as opposed to intravenously), generally in the abdominal region, as described in further detail below. Of course, it may be administered by other methods known in the art (e.g. intramuscular, oral, transdermal etc.). As with other drugs administered by subcutaneous injection, the injection site may vary periodically to adapt the treatment to injection site discomfort. In general, injections should be given in areas where the patient will not be exposed to pressure, e.g. not close to waistband or belt and not close to the ribs. Administration of degarelix by subcutaneous or intramuscular injection works well, but daily injections are generally not preferred by the patient and so a depot formulation of degarelix may be utilized as described in further detail in WO 03/006049 and U.S. Pub.
• degarelix may be conducted using a depot technology in which the peptide is released from a gel-like depot over a period of (typically) one to three months.
• Degarelix and related GnRH antagonist peptides
• Degarelix and these related GnRH antagonists are capable of forming a gel after subcutaneous injection, and this gel can act as a depot from which the peptide is released over a period of weeks or even months.
• degarelix may be provided as a powder for reconstitution (with a solvent) as solution for injection (e.g., subcutaneous injection, e.g., to form a depot as described above).
• the powder may be provided as a lyophilisate containing degarelix (e.g. as acetate) and mannitol.
• a suitable solvent is water (e.g., water for injection, or WFI).
• the solvent may be provided in vessels (e.g. vials, prefilled syringes etc.), e.g. containing 5mL or 6mL solvent.
• degarelix may be provided in a vial containing 40 mg degarelix
• degarelix may be provided in a vial containing 120 mg degarelix (acetate) for reconstitution with 3 mL WFI such that each mL of solution contains about 40 mg degarelix; reconstituting gives a 3mL solution containing about 120 mg degarelix.
• Administration e.g.
• the reconstituted solution ready for injection should be perceived as a visually clear liquid.
• the dosing regimen for degarelix may be administered as a single dose of, for example, 32 mg administered as 1 injection of 0.8 mL of about 40 mg/mL degarelix formulation.
• the dose may be repeated after a period of, for example, six or twelve months, thereby providing an "intermittent suppression" treatment of BPH.
• the dose (“effective dose”) of, for example, 32 mg of degarelix may be administered as a first dose of, for example, 16 mg, administered as 1 injection of 0.4 mL of about 40 mg/mL degarelix formulation; followed after a period of 14 days, by a second dose of, for example, 16 mg, administered as 1 injection of 0.4 mL of about 40 mg/mL degarelix formulation.
• the "effective dose” of 32 mg may be repeated (either as a single dose, or first and second 16 mg doses), after a period of, for example, twelve months, thereby providing an "intermittent suppression" treatment of BPH.
• the study aimed at exploring the potential of degarelix to induce only a short transient lowering of the serum testosterone concentration to or below the castration level, defined as 0.5 ng/mL.
• Patients diagnosed with BPH were chosen as study subjects in order to capture any signals of efficacy.
• the study population was men with BPH with: a prostate volume larger than 30 mL, a maximal uroflow of 12 mL/s (with some exceptions), an IPSS score of at least 13, serum prostatic specific antigen (PSA) below 10 ng/mL, and no evidence of prostate cancer.
• PSA serum prostatic specific antigen
• the patients were randomly allocated to receive either: one injection of 64 mg degarelix on Day 0 ("64 mg", below); one injection of 32 mg degarelix on Day 0 and one on Day 14 ("32 + 32 mg” below); one injection of 32 mg degarelix on Day 0 ("32 mg”); or one injection of 16 mg degarelix on Day 0 and one on Day 14 ("16 + 16 mg").
• the IPSS was developed in 1991 by the American Urological Association to assess the severity of urinary symptoms related to BPH (Barry, M.J., et al., The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol, 1992. 148(5): p. 1549-57; discussion 1564). It has been widely used in clinical studies, has undergone extensive validation and its psychometric properties are well documented in both the original version (containing a 1 -month recall) as well as the 'acute' version used in this study (containing a one-week recall). The WHO has recommended the use of this instrument for the evaluation of BPH and it is considered to be the internationally accepted, standard questionnaire for assessing lower urinary tract symptoms.
• the IPSS is a patient-administered questionnaire containing seven items to evaluate symptoms of urinary obstruction (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, nocturia) over the preceding week.
• Each urinary symptom question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.
• the total score can therefore range from 0 to 35 (0-7: mildly symptomatic; 8-19: moderately symptomatic; 20-35: severely symptomatic).
• a reduction in score over the treatment is indicative of improvement.
• IPSS IP-global QoL
• the Global QoL Question was developed alongside the IPSS and was officially included as part of the IPSS in 1993 when the WHO formally recommended the IPSS for both symptom and QoL assessment.
• the International Index of Erectile Function The HEF was originally developed and validated in 1996-1997 with the aim of providing a brief, reliable, self-administered measure of sexual function for use in cross cultural settings detecting treatment-related changes in patients with erectile dysfunction.
• the instrument was developed via literature review and interviews with patients with erectile dysfunction and their partners, and has been linguistically validated in 37 languages. It has been widely used as a primary endpoint in more than 50 clinical studies - including several BPH studies - and is considered the 'gold standard' measure for efficacy assessment in clinical studies of erectile dysfunction.
• the HEF meets psychometric criteria for reliability and validity and has a high degree of sensitivity and specificity.
• the MEF questionnaire evaluated sexual dysfunction associated with treatment.
• the HEF is a patient-administered questionnaire containing 15 questions covering five domains: Erectile Function (six questions), Orgasmic Function (two questions), Sexual Desire (two questions), Intercourse Satisfaction (three questions), and Overall Satisfaction (two questions).
• Question numbers one to ten are scored on a six-point scale from zero ( 1 No sexual activity') to five ('Almost always to always 1 ).
• Question numbers 11-15 are scored on a five-point scale from one ('Almost never or never') to five ('Almost always to always').
• Erectile Function domain a score of one to ten indicates severe erectile dysfunction; 11-16 moderate dysfunction; 17-21 mild to moderate dysfunction; 22-25 mild dysfunction; 26-30 no dysfunction. Also for the other domains a higher score indicates less dysfunction.
• the HEF does not yield a total score, only domain scores are calculated.
• Fig 2 shows the Comparative Change in IPSS Score in known medicinal and surgical treatments (AUA Guideline on the Management of Benign Prostatic Hyperplasia (2006). MR, Ad board and Industry reports). This confirms the superiority of surgical intervention, TURP (IPSS change of approximately -14 to -15), over the known medicinal treatments such as Tamsulosin etc (IPSS change of approximately -7.5 maximum, according to the Figure).
• degarelix treatment may provide a significant improvement over the currently available treatments such as cetrorelix and ozarelix (Debruyne et al, Cetrorelix pamoate, an LHRH antagonist, in the treatment of BPH: randomized, placebo controlled, multicenter study, Urology, 68 (Supplement 5A).
• Percentage responders defined as the number of patients that have a decrease in IPSS of at lease 30 % as compared to baseline
• Figure 1c includes the seven questions (Q1 - Q7) of the IPSS which evaluate symptoms of urinary obstruction (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, nocturia) over the preceding week. As indicated above, each urinary symptom question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. Figure 1c also includes, for each question, a graphical representation of urinary obstruction (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, nocturia) over the preceding week. As indicated above, each urinary symptom question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. Figure 1c also includes, for each question, a graphical representation of the particular symptom.
• IPSS global quality of life (QoL)
• the mean (SD) change from baseline to Day 42 was -1.2 (1.4), -2.1 (3.0), -2.4 (1.9), and -2.2 (1.6) in the 16+16, 32, 32+32, and 64 mg groups, respectively.
• Table 2 Mean IPSS global QoL score and mean change from baseline at day 42 and 6 months
• IPSS Global QoL assessment changed in the combined group from 48% feeling unhappy or terrible (scores 5 and 6) and 8% feeling delighted, pleased, or mostly satisfied (scores 0-2) at the baseline assessment, to 58% felling delighted, pleased, or mostly satisfied at the Day 42 assessment with only 12% felling unhappy or serious.
• HEF score In general, a mild decrease (i.e. slight worsening) of HEF scores was observed.
• Peak Urinary Flow, Post-void Residual Volume, and Prostate Volume were assessed in the following order:
• Peak urinary flow was determined by flowmetry using the Uropower device (Wiest, World of Medicine AG, Germany). The device fulfilled the International Continence Society standards for maximum urinary flow. The measurement of urinary flow was done in sitting position.
• the Post-void Residual Volume was evaluated by transabdominal ultrasound.
• the urine bladder was sonicated from two directions perpendicular to one another resulting in three cursor positions set by the urologist.
• the volume was calculated automatically.
• the investigations were performed by urologists by methods known in the art.
• the prostate volume was measured by transrectal ultrasound with the patient in lateral position.
• the prostatic gland was sonicated from two directions perpendicular to one another resulting in three cursor positions set by the urologist.
• the volume was calculated automatically.
• the investigations were performed by urologists by methods known in the art.
• the Qmax is the maximal urinary flow rate. It is the traditional parameter used in BPH trials and is a good indicator of degree of bladder outlet obstruction (BOO).
• the maximal urinary flow had increased on Day 42 compared to the baseline, while it decreased in 25 patients and remained unchanged in 1 patient. Twelve patients in the study violated one of the inclusion criteria by having a urinary flow of >12 mL/sec.
• the mean post-void residual volume decreased on Day 14 in all treatment groups in an apparent dose dependent way. It further decreased in the 32 mg and in the 32+32 mg group on Day 28, but returned towards, albeit still below, the baseline value on Day 42.
• the intra-group variation in urinary flow was substantial as reflected in the standard deviations and ranges.
• the post-void residual volume had decreased on Day 42 compared to the baseline, while it increased in 17 patients, distributed in all treatment groups.
• LC-MS/MS liquid chromatography method
• the greatest change from baseline was -4.0 ng/mL for the 16+16 mg, -4.2 ng/mL for the 32 mg, -4.1 ng/mL for the 32+32 mg, and -4.7 ng/mL for the 64 mg groups, respectively.
• the mean testosterone level on Day 42 was decreased in the 16+16 mg group (4.5 ng/mL vs. 5.5 ng/mL at baseline), in the 32+32 mg group (2.7 ng/mL vs. 4.5 ng/mL at baseline), and in the 64 mg group (3.0 ng/mL vs. 5.2 ng/mL at baseline) but still above the castration level.
• the mean testosterone level on Day 42 showed a small increase compared to baseline (5.3 ng/mL vs. 5.2 ng/mL at baseline).
• the mean minimal value of testosterone after each administration of degarelix (C na dir) was lower in the higher dose groups than in the lower dose groups: 0.4 ng/mL in the 64 mg group and 0.6 ng/mL (after the first administration) and 0.4 ng/mL (after the second administration) in the 32+32 mg group compared to 0.9 ng/mL in the 32 mg group and 1.4 ng/mL (after the first administration) and 2.0 ng/mL (after the second administration) in the 16+16 mg group.
• the corresponding mean time-points (tnadir) to Cnadir were calculated to be earlier in the lower dose groups than in the higher dose groups: 1.1 days after the first administration in the 16+16 mg group and 1.3 days in the 32 mg group compared to 3.2 days after the first administration in the 32+32 mg group and 8.8 days in the 64 mg group (EOT Table 11). After the second administration tnadir increased slightly and was calculated to 4.0 days and 4.3 days for the 16+16 mg and 32+32 mg groups, respectively.
• the mean time of testosterone levels below the castration level 0.5 ng/mL varied substantially between the treatment groups, the 16+16 mg group showing the shortest time and the 64 mg group the longest time. Proportion of patients at or below a testosterone level of 0.5 ng/mL at each time- point
• AUC of testosterone when testosterone level is ⁇ 0.5 ng/mL
• the mean area of testosterone concentrations below 0.5 ng/mL was 0.0 ng*Days/mL in the 16+16 mg group (range 0.0-0.0), 0.0 ng * Days/mL in the 32 mg group (range 0.0-0.1), 2.8 ng*Days/mL in the 32+32 mg group (range 0.0-15.3), and 4.4 ng * Days/mL in the 64 mg group (range 0.0-15.2).
• the calculated mean time to return to the baseline and baseline interval in the 64 mg group are not applicable.
• the calculated times for return to the baseline and baseline intervals are only hypothetical (i.e. calculated, not measured). Proportion of patients with testosterone levels at or above the baseline interval at each time point
• the administration of low doses of degarelix to patients with symptoms of BPH resulted as expected in generally transient decreases in plasma testosterone concentrations.
• the testosterone decrease was dose related as demonstrated by a more than 2-fold larger area below and longer time to return to the baseline interval in the groups given a total of 64 mg degarelix compared to the total dose 32 mg.
• the 16+16 mg administration was the most favourable dosing regimen, especially if the results from the first dose of the 32+32 mg are combined with the single dose 32 mg data, the former resulting in 2 (15%) patients castrated for less than 2 days, and the latter resulting in 8 (33%) patients castrated for generally 2-4 days.
• the overall IPSS score and the IPSS global QoL score were substantially improved in all treatment groups, indicating beneficial effects Unexpectedly, an improvement was found early on in treatment (14 days). All treatment groups demonstrated a clear effect on the prostate volume, a small effect on the post-void residual volume, and a doubtful effect on the maximal urinary flow. The 16+16 mg group showed the smallest effect in all efficacy parameters compared to the other three treatment groups.
• Administration of degarelix induced decreased levels of testosterone in all patients.
• the 16+16 and 32 mg degarelix administrations caused transient testosterone concentrations below the castration level 0.5 ng/mL in few patients, while 32+32 and 64 mg administrations caused longer sub-castration concentration periods in more patients.
• the HEF scores indicated a slight worsening of the erectile function in all treatment groups, most notably among patients with testosterone levels below the castration level on Day 42.
• a preferred range is in the region 10 to 40 mg degarelix (per dose), for example 9 to 33 mg degarelix per dose, 10 to 30 mg degarelix per dose.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Immunology (AREA)
• Epidemiology (AREA)
• Gastroenterology & Hepatology (AREA)
• Endocrinology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Reproductive Health (AREA)
• Diabetes (AREA)
• Urology & Nephrology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Plant Substances (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Orthopedics, Nursing, And Contraception (AREA)
• Detergent Compositions (AREA)
• Steroid Compounds (AREA)

Priority Applications (12)

Applications Claiming Priority (4)

Publications (2)

Family

ID=41112615

Family Applications (1)

Country Status (18)

Cited By (8)

Families Citing this family (3)

Citations (2)

Family Cites Families (22)

• 2010
  • 2010-07-02 US US12/829,467 patent/US20110039787A1/en not_active Abandoned
  • 2010-07-05 TW TW099122050A patent/TW201105344A/zh unknown
  • 2010-07-05 MX MX2012000315A patent/MX2012000315A/es active IP Right Grant
  • 2010-07-05 RU RU2011152514/15A patent/RU2011152514A/ru unknown
  • 2010-07-05 WO PCT/IB2010/001785 patent/WO2011004260A2/en not_active Ceased
  • 2010-07-05 CA CA2766008A patent/CA2766008A1/en not_active Abandoned
  • 2010-07-05 CN CN2010800295366A patent/CN102470159A/zh active Pending
  • 2010-07-05 NZ NZ597060A patent/NZ597060A/xx not_active IP Right Cessation
  • 2010-07-05 AU AU2010269958A patent/AU2010269958A1/en not_active Abandoned
  • 2010-07-05 JP JP2012519078A patent/JP2012532188A/ja active Pending
  • 2010-07-05 BR BR112012000185A patent/BR112012000185A2/pt not_active IP Right Cessation
  • 2010-07-05 US US13/381,762 patent/US20120172302A1/en not_active Abandoned
  • 2010-07-05 KR KR1020127000337A patent/KR20120038956A/ko not_active Withdrawn
  • 2010-07-05 EP EP10740272.9A patent/EP2451469B1/en not_active Not-in-force
  • 2010-07-06 SA SA110310575A patent/SA110310575B1/ar unknown
  • 2010-07-06 AR ARP100102410A patent/AR081439A1/es unknown
  • 2010-07-07 UY UY0001032769A patent/UY32769A/es not_active Application Discontinuation
• 2011
  • 2011-12-15 IL IL216987A patent/IL216987A0/en unknown
  • 2011-12-22 ZA ZA2011/09513A patent/ZA201109513B/en unknown

Patent Citations (6)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events